Daxor Corporation (NASDAQ:DXR - Get Free Report) shares rose 1.3% during trading on Monday . The stock traded as high as $10.44 and last traded at $10.5760. Approximately 4,065 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 11,264 shares. The stock had previously closed at $10.44.
Analyst Upgrades and Downgrades
DXR has been the subject of several research analyst reports. Weiss Ratings restated a "hold (c)" rating on shares of Daxor in a report on Friday, March 27th. Lake Street Capital initiated coverage on shares of Daxor in a report on Wednesday, February 11th. They issued a "buy" rating for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy".
Check Out Our Latest Report on DXR
Daxor Trading Up 1.3%
The stock's 50 day simple moving average is $10.61 and its two-hundred day simple moving average is $12.21.
Daxor (NASDAQ:DXR - Get Free Report) last announced its earnings results on Monday, March 2nd. The company reported ($0.10) earnings per share for the quarter.
Hedge Funds Weigh In On Daxor
Institutional investors and hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. bought a new position in shares of Daxor during the second quarter valued at approximately $86,000. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Daxor during the fourth quarter valued at approximately $184,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of Daxor during the first quarter valued at approximately $245,000. Institutional investors own 1.34% of the company's stock.
Daxor Company Profile
(
Get Free Report)
Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company's core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient's fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Daxor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daxor wasn't on the list.
While Daxor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
